Lantern Pharma (LTRN) News Today $4.12 +0.07 (+1.73%) As of 11:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LTRN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Lantern Pharma Reports Q2 2025 Earnings and Strategic ProgressAugust 22, 2025 | msn.comRedChip Companies, Inc.: RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26August 19, 2025 | finanznachrichten.deLantern Pharma Reports Second Quarter 2025 Financial Results and Business UpdatesAugust 13, 2025 | businesswire.comLantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% AccuracyAugust 7, 2025 | theglobeandmail.comLantern Pharma (LTRN) Expected to Announce Quarterly Earnings on ThursdayAugust 7, 2025 | marketbeat.comShort Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Grows By 109.5%August 6, 2025 | marketbeat.comLantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™August 4, 2025 | businesswire.comLantern Pharma (LTRN) Gets a Buy from Lake StreetAugust 4, 2025 | theglobeandmail.comLantern Pharma (NASDAQ: LTRN) Completes Targeted Enrollment for Phase 2 HARMONIC Trial in JapanJuly 31, 2025 | theglobeandmail.comLantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300July 31, 2025 | businesswire.comLantern Pharma Appoints Dr. Schalop to BoardJuly 30, 2025 | msn.comLantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision OncologyJuly 28, 2025 | theglobeandmail.comLantern Pharma Announces Appointment of Dr. Lee Schalop to Board of DirectorsJuly 28, 2025 | businesswire.comLantern reports complete response in pretreated Lymphoma patient with LP-284July 24, 2025 | msn.comLantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical TrialJuly 23, 2025 | businesswire.comLantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer TherapyJuly 21, 2025 | businesswire.comIBN Initiates Coverage of Lantern Pharma Inc.July 16, 2025 | finance.yahoo.comLantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer TreatmentJuly 15, 2025 | theglobeandmail.comLantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer TreatmentJuly 15, 2025 | businesswire.comNASDAQ:LTRN Financials | Lantern Pharma Inc - Investing.comJuly 9, 2025 | investing.comLantern Pharma Enters ATM Sales Agreement with ThinkEquityJuly 3, 2025 | tipranks.comLung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two YearsJune 16, 2025 | businesswire.comLantern Pharma Inc. (NASDAQ:LTRN) Major Shareholder Aaron G.L. Fletcher Sells 40,000 SharesJune 14, 2025 | insidertrades.comHere's Why We're Watching Lantern Pharma's (NASDAQ:LTRN) Cash Burn SituationMay 31, 2025 | finance.yahoo.comLantern Pharma Inc. (NASDAQ:LTRN) Major Shareholder Sells $43,050.00 in StockMay 30, 2025 | insidertrades.comLantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor ModelsMay 29, 2025 | insidermonkey.comLantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical TrialsMay 29, 2025 | businesswire.comLTRN: First Quarter 2025 Financial ResultsMay 20, 2025 | finance.yahoo.comEarnings call transcript: Lantern Pharma Q1 2025 reports narrower lossMay 17, 2025 | uk.investing.comLantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comLantern Pharma Inc. (LTRN) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comLantern Pharma Reports First Quarter 2025 Financial Results and Business UpdatesMay 15, 2025 | businesswire.comLantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ETMay 8, 2025 | businesswire.comLTRN: IND Clearance for LP-184 in TNBCMay 6, 2025 | msn.comLantern Pharma Stock Short Interest Report | NASDAQ:LTRN | BenzingaMay 6, 2025 | benzinga.comEXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage TrialMay 5, 2025 | uk.finance.yahoo.comLantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)May 5, 2025 | businesswire.comLantern Pharma initiated with a Buy at Lake StreetApril 3, 2025 | markets.businessinsider.comLake Street Initiates Coverage of Lantern Pharma (LTRN) with Buy RecommendationApril 3, 2025 | msn.comEarnings call transcript: Lantern Pharma’s Q4 2024 results show increased R&D expensesMarch 29, 2025 | uk.investing.comLTRN: 2024 Financial ResultsMarch 28, 2025 | finance.yahoo.comLantern Pharma outlines 2025 clinical milestones and key updates on oncology trialsMarch 27, 2025 | msn.comLantern Pharma Inc. (LTRN) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comLantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial ResultsMarch 27, 2025 | businesswire.comPreview: Lantern Pharma's EarningsMarch 27, 2025 | benzinga.comLTRN: M&A Illuminates GBM ValueMarch 10, 2025 | finance.yahoo.comLantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction TechFebruary 20, 2025 | insidermonkey.comLantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction TechFebruary 20, 2025 | msn.comLantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer TherapiesJanuary 27, 2025 | insidermonkey.comLantern Pharma Inc. (LTRN): AI-Driven Cancer Drug DevelopmentJanuary 17, 2025 | insidermonkey.com Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LTRN Media Mentions By Week LTRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LTRN News Sentiment▼0.930.99▲Average Medical News Sentiment LTRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LTRN Articles This Week▼21▲LTRN Articles Average Week Get the Latest News and Ratings for LTRN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Lantern Pharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies MDWD News RAPT News OGI News EPRX News KRRO News TNYA News ENGN News TIL News SXTC News CRBU News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LTRN) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access